Clinical trials
Recurrent or Metastatic Cervical Cancer clinical trials
Below are recruiting recurrent or metastatic cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 3,905 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07340164RecruitingPhase 2
Trastuzumab deruxtecan vs standard care for recurrent ovarian cancer
This trial compares a targeted drug called trastuzumab deruxtecan to standard treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after previous treatment with a PARP inhibitor. The study is for patients whose tumors show a certain level of a protein called HER2 on their surface.
Seoul, SeoulAges 18 years+ - NCT06022029RecruitingPhase 1
Study of injected ONM-501 alone or with cemiplimab for advanced cancers
This trial tests an injected study drug (ONM-501) alone or with another drug (cemiplimab) for people with advanced solid tumors or lymphomas that haven't responded to other treatments. It aims to find a safe dose and see if the combination helps shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06538012RecruitingPhase 1/Phase 2
Tumor immune cells plus pembrolizumab for advanced lung cancer
This trial tests a new approach: taking immune cells from your own tumor (TILs), growing them in the lab, then giving them back to you along with the immunotherapy drug pembrolizumab. It is for people with advanced lung cancer who have run out of standard options.
Beijing, Beijing MunicipalityAges 16–90 - NCT07444814RecruitingPhase 1
HWK-007 for advanced solid tumors
This trial tests a new drug called HWK-007, which is designed to target and attack cancer cells while sparing healthy ones. It is for people with specific advanced solid tumors (lung, endometrial, or ovarian cancer) that have not responded well to standard treatments.
Little Rock, ArkansasAges 18 years+ - NCT07311577RecruitingPhase 2
Trial of a drug combo for HER2-positive ovarian cancer
This trial tests a combination of disitamab vedotin, platinum chemotherapy, and bevacizumab as first treatment for high-risk ovarian cancer that has a protein called HER2. The goal is to see if this therapy helps control the cancer and keeps it from growing.
Nanjing, JiangsuAges 18–75 - NCT07050394RecruitingEarly Phase 1
Experimental drug for advanced colorectal cancer
This trial tests a new experimental drug (HNF4α srRNA) given through a vein for people with advanced colorectal cancer that has not responded to or cannot be treated with standard therapies. The goal is to see if this treatment can help shrink or slow the growth of the cancer.
Shanghai, None SelectedAges 18 years+ - NCT07197580RecruitingPhase 3
Study of a targeted radiation therapy for advanced kidney cancer
This trial tests a new drug called 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for people with advanced clear cell renal cell carcinoma that has returned or not responded to at least 2 prior treatments.
Sydney, New South WalesAges 18 years+ - NCT06654336RecruitingPhase 2
Targeted therapy with or without hormone therapy for prostate cancer that has spread a little
This trial tests whether targeting the spots where cancer has returned with radiation or surgery, with or without hormone therapy, can help control prostate cancer that has come back in a few places after previous treatment.
Hamilton, OntarioAges 18 years+ - NCT06455046RecruitingPhase 2
New drug combo for advanced cervical cancer
This trial tests a new drug called AK104 combined with chemotherapy and a virus-based therapy for cervical cancer that has come back or spread. It might help people who have already tried standard treatments and need new options.
Fuzhou, FujianAges 18–75 - NCT04521764RecruitingPhase 1
Vaccine for Metastatic Breast Cancer
This trial tests a vaccine (MV-s-NAP) that is injected directly into a tumor to stimulate your immune system against breast cancer. It is for people with metastatic breast cancer that has spread despite prior treatments.
Rochester, MinnesotaAges 18 years+ - NCT03418961RecruitingPhase 3
Study of heart-risk management for metastatic HER2 breast cancer
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
Anchorage, AlaskaAges 18 years+ - NCT04119024RecruitingPhase 1
Gene-edited immune cells for advanced melanoma or solid tumors
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
Duarte, CaliforniaAges 18–75 - NCT06867445Recruiting
Minimally invasive surgery for recurrent cervical or vaginal cancer
This trial tests a minimally invasive surgery (using small incisions) to remove a pelvic tumor that has come back after treatment for vaginal or cervical cancer. It aims to see if this approach can safely remove the recurrence while avoiding more extensive surgery.
RomeAges 18 years+ - NCT06992648RecruitingPhase 3
Two drug combos for advanced colorectal cancer
This trial tests a two-drug combination (trifluridine/tipiracil plus regorafenib) against a standard pair (trifluridine/tipiracil plus bevacizumab) for people with advanced colorectal cancer that has stopped responding to prior treatments. It aims to find which combination works better.
Hangzhou, ZhejiangAges 18 years+ - NCT04529044RecruitingPhase 2
177Lu-DOTATATE for advanced breast cancer with targeted receptors
This Phase 2 trial tests whether 177Lu-DOTATATE can slow or shrink stage IV or recurrent breast cancer. It targets tumor “receptors” found on scans, using a radioactive medicine that delivers radiation directly to cancer cells.
Portland, OregonAges 18–100 - NCT06324240RecruitingPhase 1
Personalized vaccine plus immunotherapy for triple-negative breast cancer
This trial tests a personalized vaccine made from your tumor combined with immunotherapy drugs (pembrolizumab or ipilimumab) for triple-negative breast cancer. It aims to help your immune system recognize and attack cancer cells.
Atlanta, GeorgiaAges 18 years+ - NCT06242470RecruitingPhase 1
Study of MGC026 for advanced solid tumors
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
Los Angeles, CaliforniaAges 18 years+ - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+ - NCT06999187RecruitingPhase 1
Study of DR-0202 for advanced solid tumors after multiple treatments
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
Denver, ColoradoAges 18 years+ - NCT07227168RecruitingPhase 1
Study of STRO-004 for advanced solid tumors
This trial tests a new drug called STRO-004 for people with advanced solid tumors (cancers that have spread or come back). It aims to see if the drug is safe and effective for those who have already tried other treatments.
San Diego, CaliforniaAges 18 years+ - NCT06677190RecruitingPhase 2
Belzutifan for Recurrent Clear Cell Gynecologic Cancer
This study tests a daily pill called belzutifan for people with a rare type of gynecologic cancer (clear cell carcinoma) that has come back or not gone away after standard treatments. The drug works by targeting a protein that helps tumors grow when oxygen levels are low.
Boston, MassachusettsAges 18 years+ - NCT06800612Recruiting
Cancer drug therapy study for gynecologic or breast cancers
This study looks at how well different cancer drugs work for women with breast or gynecologic cancers. Researchers will review medical records to see how patients responded to treatment over time. If you have been treated for breast or gynecologic cancer since 2010, you may be eligible.
BolognaAges 18 years+ - NCT07189871RecruitingPhase 1/Phase 2
177Lu-BetaBart for advanced solid tumors
This trial tests a new radioactive drug, 177Lu-BetaBart, for people with certain advanced solid tumors that have stopped responding to other treatments. The goal is to see if it can shrink tumors or slow their growth.
Dothan, AlabamaAges 18 years+
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic cervical cancer?
- Yes. Clin2 currently lists 3,905 recruiting recurrent or metastatic cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.